Get the Stockscreener App
8.865
0.67%
-0.065
Aurinia Pharmaceuticals Inc stock is traded at $8.865, with a volume of 138.63K.
It is down -0.67% in the last 24 hours and up +2.66% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$8.93
Open:
$8.95
24h Volume:
138.63K
Relative Volume:
0.10
Market Cap:
$1.20B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-16.73
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
+2.90%
1M Performance:
+2.66%
6M Performance:
+7.65%
1Y Performance:
+56.16%
1-Day Range:
$8.815
$8.96
1-Week Range:
$8.55
$9.36
52-Week Range:
$5.195
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
8.865 | 1.21B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.16 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.88 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.73 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.91 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.15 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Does Aurinia Pharmaceuticals Inc. stock perform well during market downturnsSuperior portfolio returns - jammulinksnews.com
Why is Aurinia Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize your portfolio’s earning power - jammulinksnews.com
What is the risk reward ratio of investing in Aurinia Pharmaceuticals Inc. stockGet professional advice for market timing - jammulinksnews.com
Is Aurinia Pharmaceuticals Inc. a growth stock or a value stockAchieve breakthrough investment performance - jammulinksnews.com
Should I hold or sell Aurinia Pharmaceuticals Inc. stock in 2025Skyrocketing returns - jammulinksnews.com
What is Aurinia Pharmaceuticals Inc. company’s growth strategyUnlock powerful portfolio optimization tools - jammulinksnews.com
What makes Aurinia Pharmaceuticals Inc. stock price move sharplyAccelerated wealth expansion - jammulinksnews.com
Can Aurinia Pharmaceuticals Inc. stock recover from recent decline200 Percent Gain Alert - Metal.it
Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - PrintWeekIndia
Will Aurinia Pharmaceuticals Inc. stock split in the near futureMarket-leading growth rates - jammulinksnews.com
What analysts say about Aurinia Pharmaceuticals Inc. stockRapid growth opportunities - Autocar Professional
When is the best time to buy Aurinia Pharmaceuticals Inc. stockSuperior profit margins - jammulinksnews.com
Is Aurinia Pharmaceuticals Inc. a good long term investmentTremendous gains - PrintWeekIndia
What drives Aurinia Pharmaceuticals Inc. stock priceUnmatched profit growth - Autocar Professional
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - Zenopa
Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 04 '25 |
Sale |
7.92 |
57,607 |
456,247 |
509,276 |
| Donley Matthew Maxwell | Chief Operating Officer |
Mar 03 '25 |
Sale |
8.00 |
65,902 |
527,216 |
739,456 |
| Donley Matthew Maxwell | Chief Operating Officer |
Mar 04 '25 |
Sale |
7.92 |
58,991 |
467,209 |
680,465 |
| TANG KEVIN | Director |
Mar 04 '25 |
Buy |
7.96 |
748,038 |
5,953,304 |
10,029,500 |
0.43%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):